Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis

References

• 1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), e359–e386 (2015).
  Medline CASGoogle Scholar
• 2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374–1403 (2013).
  Medline CASGoogle Scholar
• 3 van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin. Exp. Metastasis 32(5), 457–465 (2015).
  Medline CASGoogle Scholar
• 4 Rubbia-Brandt L, Giostra E, Brezault C et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 18(2), 299–304 (2007).
  Medline CASGoogle Scholar
• 5 Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg. 255(3), 534–539 (2012).
  MedlineGoogle Scholar
• 6 Schwarz L, Michel P, Scotté M. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg. 261(1), e28–e29 (2015).
  MedlineGoogle Scholar
• 7 Elias D, Goere D, Boige V et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann. Surg. Oncol. 14(11), 3188–3194 (2007).
  MedlineGoogle Scholar
• 8 Fiorentini G, Del Conte A, De Simone M et al. Complete response of colorectal liver metastases after intraarterial chemotherapy. Tumori 94, 489–492 (2008).
  Medline CASGoogle Scholar
• 9 Tanaka K, Takakura H, Takeda K et al. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann. Surg. 250(6), 935–942 (2009).
  MedlineGoogle Scholar
• 10 Auer RC, White RR, Kemeny NE et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116(6), 1502–1509 (2010).
  MedlineGoogle Scholar
• 11 Carpenter S, Fong Y. Management of disappearing colorectal hepatic metastases. Adv. Surg. 44, 269–279 (2010).
  MedlineGoogle Scholar
• 12 van Vledder MG, de Jong MC, Pawlik TM et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J. Gastrointest. Surg. 14(11), 1691–1700 (2010).
  MedlineGoogle Scholar
• 13 Ono T, Ishida H, Kumamoto K et al. Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy. Oncol. Lett. 4(5), 905–909 (2012).
  Medline CASGoogle Scholar
• 14 Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245–255 (2011).
  Medline CASGoogle Scholar
• 15 Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet 381(9863), 303–312 (2013).
  Medline CASGoogle Scholar
• 16 Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet 381(9863), 295–302 (2013).
  Medline CASGoogle Scholar
• 17 Li J, Qin S, Yau T et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 16(6), 619–629 (2015).
  Medline CASGoogle Scholar
• 18 Chun YS, Vauthey JN, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302(21), 2338–2344 (2009).
  Medline CASGoogle Scholar
• 19 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 20 van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur. Radiol. 20(6), 1456–1467 (2010).
  MedlineGoogle Scholar
• 21 Lim Y, Han SW, Yoon JH et al. Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer. PLoS ONE 10, e0145004 (2015).
  MedlineGoogle Scholar
• 22 Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a Phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14(1), 22–28 (2009).
  Medline CASGoogle Scholar
• 23 Choi H, Charnsangavej C, de Castro Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol. 183(6), 1619–1628 (2004).
  MedlineGoogle Scholar
• 24 Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753–1759 (2007).
  MedlineGoogle Scholar
• 25 Kang H, Lee HY, Lee KS et al. Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J. Radiol. 13(4), 371–390 (2012).
  MedlineGoogle Scholar
• 26 Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091–2096 (2009).
  MedlineGoogle Scholar
• 27 Chung WS, Park MS, Shin SJ et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am. J. Roentgenol. 199(4), 809–815 (2012).
  MedlineGoogle Scholar
• 28 Shinagare AB, Jagannathan JP, Kurra V et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur. J. Cancer 50(5), 981–986 (2014).
  Medline CASGoogle Scholar
• 29 Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118(1), 147–156 (2012).
  Medline CASGoogle Scholar
• 30 Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am. J. Roentgenol. 194(1), 157–165 (2010).
  MedlineGoogle Scholar
• 31 Smith AD, Shah SN, Rini BI et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am. J. Roentgenol. 194(6), 1470–1478 (2010).
  MedlineGoogle Scholar
• 32 Nishino M, Cryer SK, Okajima Y et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging 12, 225–235 (2012).
  MedlineGoogle Scholar
• 33 Reginelli A, Vanzulli A, Sgrazzutti C et al. Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies. Med. Oncol. 34(5), 93 (2017).
  MedlineGoogle Scholar
• 34 Reginelli A, Silvestro G, Fontanella G et al. Performance status versus anatomical recovery in metastatic disease: the role of palliative radiation treatment. Int. J. Surg. 33(Suppl. 1), S126–S131 (2016).
  MedlineGoogle Scholar
• 35 Ierardi AM, Floridi C, Fontana F et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. Radiol. Med. 118(6), 949–961 (2013).
  MedlineGoogle Scholar
• 36 Carrafiello G, Fontana F, Cotta E et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases. Radiol. Med. 116(7), 1059–1066 (2011).
  Medline CASGoogle Scholar
• 37 Scialpi M, Palumbo B, Pierotti L et al. Detection and characterization of focal liver lesions by split-bolus multidetector-row CT: diagnostic accuracy and radiation dose in oncologic patients. Anticancer Res. 34(8), 4335–4344 (2014).
  MedlineGoogle Scholar
• 38 Floridi C, Pesapane F, Angileri SA et al. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med. Oncol. 34(10), 174 (2017).
  Medline CASGoogle Scholar
• 39 Ricotta R, Verrioli A, Ghezzi S et al. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT Phase III trial (RadioCORRECT study). ESMO Open 1, e000111 (2017).
  MedlineGoogle Scholar
• 40 Sforza V, Martinelli E, Cardone C et al. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open 2, e229 (2017).
  Google Scholar
• 41 Sforza V, Martinelli E, Ciardiello F et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J. Gastroenterol. 22(28), 6345–6361 (2016).
  MedlineGoogle Scholar
• 42 Floridi C, Radaelli A, Pesapane F et al. Clinical impact of cone beam computed tomography on iterative treatment planning during ultrasound-guided percutaneous ablation of liver malignancies. Med. Oncol. 34(6), 113 (2017).
  MedlineGoogle Scholar